Therapy Name | Anti-VEGFR2 CAR CD8 lymphocytes |
Therapy Description |
Anti-VEGFR2 CAR CD8 lymphocytes consists of patient's own T-lymphocytes transduced with a recombinant retroviral vector encoding a chimeric T cell receptor specific for KDR (VEGFR2), expanded and reintroduced into the patient. The cells bind to and subsequently lyse VEGFR2-expressing cells (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Anti-VEGFR2 CAR CD8 lymphocytes | VEGFR2 Immune Cell Therapy 1 | Anti-VEGFR2 CAR CD8 lymphocytes consists of patient's own T-lymphocytes transduced with a recombinant retroviral vector encoding a chimeric T cell receptor specific for KDR (VEGFR2), expanded and reintroduced into the patient. The cells bind to and subsequently lyse VEGFR2-expressing cells (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References | KDR positive | melanoma | predicted - sensitive | Anti-VEGFR2 CAR CD8 lymphocytes | Preclinical | Actionable | In a preclinical study, Anti-VEGFR2 CAR CD8 lymphocytes increased survival of melanoma mouse models (PMID: 23633494). | 23633494 | KDR positive | Advanced Solid Tumor | predicted - sensitive | Anti-VEGFR2 CAR CD8 lymphocytes | Preclinical | Actionable | In a preclinical study, Anti-VEGFR2 CAR CD8 lymphocytes, displayed efficacy in inhibiting cell and tumor growth in a variety of solid tumor cell lines and mouse tumor models (PMID: 20978347). | 20978347 |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status |
---|---|---|---|---|
NCT01218867 | Phase Ib/II | Anti-VEGFR2 CAR CD8 lymphocytes Cyclophosphamide Fludarabine Aldesleukin | Treating Metastatic Cancer With Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes | Completed |